NCT04370470

Brief Summary

Later Stage HD Assessments (LSA) is an observational, multinational study aiming at developing two assessments that can be used to measure critical milestones and events during the later stages of Huntington's disease (HD). An important aspect of the evaluation will be to assess whether the assessments can be administered to a companion either in-person or remotely (i.e. by phone contact with the companion). Therefore, these assessments will be evaluated for their internal consistency, reliability and validity. Once established, these assessments may be incorporated into a large scale, global observational study of HD and/or other HD clinical studies as well as use them for planning clinical trials.

Trial Health

47
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
340

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2020

Geographic Reach
2 countries

20 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 1, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

May 1, 2020

Status Verified

January 1, 2020

Enrollment Period

1.5 years

First QC Date

April 24, 2020

Last Update Submit

April 28, 2020

Conditions

Keywords

CHDIHuntington DiseaseHuntington's DiseaseHuntington's Disease Later Stage

Outcome Measures

Primary Outcomes (2)

  • The UHDRS SIF ratings

    The equivalence of the original UHDRS function scales (TFC, FAS and IS) and the UHDRS SIF will be evaluated using a cross-over design study, with two baseline measurements and one follow up measurement. We will use ICC (Intraclass Correlation Coefficient) and Lin's correlation coefficient will be used to measure the agreement between raters across Participants.

    3 weeks

  • Clinimetric properties of the UHDRS SIF

    To assess the clinimetric properties of the UHDRS SIF we will use Classical Test Theory (CTT) and Item Response Theory (IRT)

    3 weeks

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Manifest HDGEC Participants: Manifest HDGEC Participants must be participants in the Enroll-HD study. Manifest HDGEC Participants will be recruited from English-speaking study sites participating in the Enroll-HD study. Companion Participants: Companions Participants will be identified for Manifest HDGEC Participants and asked to participate. A Companion Participant's participation for a Manifest HDGEC participant is mandatory.

You may qualify if:

  • All Participants
  • Individual of either gender
  • Fluent in English
  • Must be willing and able to provide informed consent or have a legal representative willing and able to provide assent
  • Manifest HDGEC Participants
  • Must be an active participant in the Enroll-HD study. An active participant is defined as a participant who has successfully enrolled in the Enroll-HD study and completed the Enroll-HD study baseline visit.
  • Age≥20 years
  • CAG repeat length≥36
  • DCL=4
  • \. Age≥18 years 2. A person who, in his/her opinion, has sufficient interface and knowledge of the Manifest HDGEC Participant's capabilities and daily activities 3. Acceptable to the Manifest HDGEC Participant and the Site Investigator or the Site Investigator's designees

You may not qualify if:

  • People who meet the following criteria will be excluded from participating in this study:
  • Individuals with choreic movement disorders in the context of a laboratory verified non-expansion mutation for the Huntingtin gene
  • Manifest HDGEC Participants with Juvenile-onset HD (rater estimate of age of onset \<20 years old)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (20)

The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Location

Regents of the University of California, San Diego

La Jolla, California, 92037, United States

Location

Regents of the University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

Rocky Mountain Movement Disorders Center, P.C

Englewood, Colorado, 80113, United States

Location

Rush Universiity Medical Center

Chicago, Illinois, 60612, United States

Location

Hereditary Neurological Disease Centre, Inc.

Wichita, Kansas, 67226, United States

Location

Washington University

St Louis, Missouri, 63110, United States

Location

Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

Location

University of Washington

Seattle, Washington, 98195, United States

Location

The Chancellor, Masters and Scholars of the University of Cambridge

Cambridge, Cambridgeshire, CB2 0PY, United Kingdom

Location

Cardiff University

Wales, Cardiff, CF144XN, United Kingdom

Location

Royal Devon and Exeter NHS Foundation Trust

Exeter, Devon, EX2 5DW, United Kingdom

Location

Poole Hospital NHS

Poole, Dorset, BH15 2JB, United Kingdom

Location

Leicestershire Partnership NHS Trust

Leicester, Leicestershire, LE2 2PL, United Kingdom

Location

Oxford University Hospitals NHS Foundation Trust

Oxford, Leicester, OX3 9DU, United Kingdom

Location

Northumberland, Tyne &Wear NHS Foundation Trust of St. Nicholas Hospital

Newcastle upon Tyne, Tyne & Wear, NE6 4QD, United Kingdom

Location

Birmingham and Solihull Mental Health NHS Foundation

Birmingham, West Midlands, B152FG, United Kingdom

Location

Leeds Teaching Hospitals NHS Trust

Leeds, Yorkshire, LS7 4SA, United Kingdom

Location

University Hospitals Plymouth NHS Trust

Plymouth, PL6 8BQ, United Kingdom

Location

Sheffield Children's NHS Foundation Trust

Sheffield, S5 7AU, United Kingdom

Location

MeSH Terms

Conditions

Huntington Disease

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDementiaChoreaDyskinesiasMovement DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCognition DisordersNeurocognitive DisordersMental Disorders

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
21 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2020

First Posted

May 1, 2020

Study Start

September 1, 2020

Primary Completion

March 1, 2022

Study Completion

March 1, 2022

Last Updated

May 1, 2020

Record last verified: 2020-01

Locations